Zomedica Corp. (ZOM): Price and Financial Metrics

Zomedica Corp. (ZOM): $0.21

-0.01 (-5.59%)

POWR Rating

Component Grades














  • Growth is the dimension where ZOM ranks best; there it ranks ahead of 70.54% of US stocks.
  • The strongest trend for ZOM is in Sentiment, which has been heading up over the past 47 days.
  • ZOM's current lowest rank is in the Stability metric (where it is better than 1.71% of US stocks).

ZOM Stock Summary

  • With a price/sales ratio of 79.66, Zomedica Corp has a higher such ratio than 97.25% of stocks in our set.
  • ZOM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 5.6% of US stocks.
  • As for revenue growth, note that ZOM's revenue has grown 13,761.63% over the past 12 months; that beats the revenue growth of 99.81% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Zomedica Corp, a group of peers worth examining would be EVOK, EBET, MICT, BLDE, and RIOT.
  • Visit ZOM's SEC page to see the company's official filings. To visit the company's web site, go to www.zomedica.com.

ZOM Valuation Summary

  • ZOM's EV/EBIT ratio is -19.6; this is 166.89% lower than that of the median Healthcare stock.
  • ZOM's price/sales ratio has moved NA NA over the prior 46 months.
  • ZOM's price/sales ratio has moved NA NA over the prior 46 months.

Below are key valuation metrics over time for ZOM.

Stock Date P/S P/B P/E EV/EBIT
ZOM 2021-08-31 20836.7 2.3 -34.9 -19.6
ZOM 2021-08-30 20216.7 2.2 -33.9 -18.5
ZOM 2021-08-27 20640.0 2.2 -34.6 -19.2
ZOM 2021-08-26 22533.3 2.4 -37.8 -22.4
ZOM 2021-08-25 18940.0 2.1 -31.7 -16.4
ZOM 2021-08-24 16623.3 1.8 -27.9 -12.5

ZOM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZOM has a Quality Grade of F, ranking ahead of 3.62% of graded US stocks.
  • ZOM's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ZOM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 -0.393 -5.936
2021-03-31 0 0.599 -5.609
2020-12-31 0 NA -5.395
2020-09-30 0 NA -6.260
2020-06-30 0 NA -6.329
2020-03-31 0 NA -5.504

ZOM Stock Price Chart Interactive Chart >

Price chart for ZOM

ZOM Price/Volume Stats

Current price $0.21 52-week high $0.81
Prev. close $0.22 52-week low $0.18
Day low $0.21 Volume 23,201,000
Day high $0.22 Avg. volume 19,267,205
50-day MA $0.24 Dividend yield N/A
200-day MA $0.35 Market Cap 203.62M

Zomedica Corp. (ZOM) Company Bio

Zomedica Pharmaceuticals Corp. operates as a veterinary pharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of drugs, novel drug delivery systems, devices, and diagnostics for the health and wellness of companion animals, such as canine, feline, and equine. The company has a research collaboration agreement with Celsee Diagnostics, Inc. to test the feasibility of Celsee's liquid biopsy technology for veterinary application as a canine cancer diagnostics. Zomedica Pharmaceuticals Corp. was founded in 2015 and is based in Ann Arbor, Michigan.

ZOM Latest News Stream

Event/Time News Detail
Loading, please wait...

ZOM Latest Social Stream

Loading social stream, please wait...

View Full ZOM Social Stream

Latest ZOM News From Around the Web

Below are the latest news stories about Zomedica Corp that investors may wish to consider to help them evaluate ZOM as an investment opportunity.

Dogs Win, Investors Lose With Zomedica

Zomedica said last year that Truforma would revolutionize veterinary care with radio waves.

Dana Blankenhorn on InvestorPlace | March 24, 2022

It’s Going to Take a Lot to Get Zomedica Stock Out of the Doghouse

ZOM stockholders are likely to grow increasingly frustrated with management's misplaced optimism and the lack of Truforma sales.

Muslim Farooque on InvestorPlace | March 10, 2022

Will the PulseVet Acquisition Continue to Deliver Sales for Zomedica?

Zomedica Corp.

Stavros Georgiadis on InvestorPlace | March 3, 2022

Zomedica Corporation Reports 2021 Fourth Quarter & Full Year Results

ANN ARBOR, MI / ACCESSWIRE / March 1, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today reported consolidated financial results for the year ended December 31, 2021.

Yahoo | March 1, 2022

Zomedica Announces Participation in the Q1 Virtual Investor Summit

Ann Arbor, Michigan--(Newsfile Corp. - February 28, 2022) - Zomedica (AMEX: ZOM) today announced that Larry Heaton, CEO will be attending the Q1 Virtual Investor Summit. During the presentation, Zomedica’s Chief Executive Officer, Larry Heaton, will highlight the Company's recent integration of PulseVet, Inc., it's progress with the TRUFORMA product line, and the resulting transformational business strategy and partnerships, and the broader going-forward corporate vision. The presentation will b

Yahoo | February 28, 2022

Read More 'ZOM' Stories Here

ZOM Price Returns

1-mo -15.90%
3-mo -36.13%
6-mo -35.98%
1-year -73.08%
3-year -16.00%
5-year -88.08%
YTD -31.48%
2021 32.91%
2020 -30.33%
2019 -73.09%
2018 -37.88%
2017 91.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.4832 seconds.